Related Experiment Videos
A view from Europe
1Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Hospital, Gothenburg University, Sweden.
Insights
Certain beta-receptor antagonists and aspirin effectively prevent sudden cardiac death. Other cardiovascular drugs, like thiazide diuretics and calcium antagonists, do not reduce sudden cardiac death despite other benefits.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Coronary protection aims to prevent sudden death and myocardial infarction without increasing noncardiac mortality.
- The efficacy of treating mild hypertension and hypercholesterolemia pharmacologically requires critical evaluation.
- There is a need for robust, randomized clinical trials with definitive endpoints to assess cardioprotective capabilities.
Purpose of the Study:
- To critically discuss the pharmacologic approaches to coronary protection.
- To evaluate the effectiveness of various drug classes in preventing sudden cardiac death.
- To emphasize the importance of well-designed clinical trials for determining cardioprotective effects.
Main Methods:
- Review of existing randomized clinical trials with definitive endpoints.
- Analysis of pharmacologic agents used for cardiovascular disease management.
- Discussion of the pathophysiology of sudden cardiac death.
Main Results:
- Some beta-receptor antagonists and aspirin have demonstrated protection against sudden cardiac death.
- Thiazide diuretics, calcium antagonists, and angiotensin-converting enzyme inhibitors have not shown a reduction in sudden cardiac death.
- Individual drugs within these classes may offer other cardiovascular benefits.
Conclusions:
- Beta-receptor antagonists and aspirin are established agents for preventing sudden cardiac death.
- The role of other drug classes in preventing sudden cardiac death remains unproven.
- Pharmacokinetic differences among beta blockers may influence their cardioprotective effects.
Abstract:
The pharmacologic approach to coronary protection, defined here as the prevention or delay of sudden death and myocardial infarction (without negatively affecting noncardiac mortality), is critically discussed. The value of pharmacologically treating mild hypertension and mild hypercholesterolemia is questioned, and the need for well-designed, randomized clinical trials with definitive endpoints to determine a drug's cardioprotective capability is emphasized. Based on such studies, it is concluded that some (but perhaps not all) beta-receptor antagonists as well as aspirin have been shown to protect against sudden cardiac death. Trials of thiazide diuretics, calcium antagonists, and angiotensin-converting enzyme inhibitors have not shown a reduction in sudden cardiac death, despite having individual benefits with respect to other aspects of cardiovascular disease. The demonstration that some beta blockers are cardioprotective is discussed in terms of the pathophysiology of sudden cardiac death, and differences in the pharmacokinetic profiles of individual agents.